

## High Risk GI Cancer Clinic

In January 2011, the UNC GI Division in collaboration with the Departments of Genetics and Surgery opened a high risk GI cancer clinic. The clinic is designed to provide multidisciplinary care to patients and family with known or suspected inherited conditions.



Robert Sandler, MD  
UNC GI Division Chief

There are several genetic conditions that profoundly increase the risk for gastrointestinal malignancies. Patients with Familial Adenomatous Polyposis (FAP), for example, have a 100% lifetime risk of colorectal cancer if they do not undergo colectomy, and a 10% risk of duodenal cancer. Patients with Lynch syndrome have a 60% lifetime risk of colorectal cancer; women with the disorder have a 40% lifetime risk for endometrial cancer. Other genetic conditions including MYH polyposis, Cowden's syndrome, hyperplastic polyposis, and Peutz-Jeghers syndrome carry an extremely high risk for cancer at multiple sites. Because the conditions are inherited, family members may be affected and are at risk.

In the past, the care for these high risk patients was disorganized. Care was provided by gastroenterologists, surgeons, geneticists and primary care physicians at UNC and across the state. Most providers did not have the volume of patients or the expertise to provide optimal care or to keep up with the latest guidelines. There was also no coherent system to identify, educate, screen and monitor these patients.

The High Risk Clinic is designed to address these issues. The clinic provides true multidisciplinary care where patients can be seen by each discipline during the same visit. In addition the clinic is developing a registry that will keep track of needed surveillance testing. Registered patients will have access to the latest breakthroughs.

The clinic has an important educational mission as well. We do our best to provide patients and families with the information that they need as we treat them with compassion, respect and the highest standards of medical care.

The clinic gastroenterologist is Robert Sandler, MD, MPH, Distinguished Professor of Medicine and Epidemiology. James P. Evans MD, Distinguished Professor of Genetics and Medicine and Catherine Fine, MS, CGC provide genetic support. Timothy Sadiq, MD, Assistant Professor of Surgery handles the surgical aspects to care.

To our knowledge, the closest clinic of this type is at Johns Hopkins. Establishing a high risk clinic of this type provides an important service to patients and our medical colleagues. If you would like to refer a patient call our toll free number (877) 668-0680 or obtain a referral form from our website (<http://www.med.unc.edu/gi/for-outside-physicians>). If you have questions call Dr. Sandler at 919-966-0090.

## Alumni Notes

We will be reporting news and updates from alumni of our GI fellowship program. If you have any updates, events, or news you'd like included in the Newsletter, please send an e-mail to [jvherath@unc.edu](mailto:jvherath@unc.edu).

Over the past 3 years, we have been working to improve our website, [www.med.unc.edu/gi](http://www.med.unc.edu/gi), keeping it up to date with the most current news, and creating a whole new look. We now want to include our former fellows by establishing an Alumni page. This would be an effective way for alumni to stay in touch with our division. Because patients come to our website it might also be a way to promote patient referrals.

If you would like to be included, please respond to Joanna Herath [jvherath@med.unc.edu](mailto:jvherath@med.unc.edu), and confirm your graduation date from the division, office phone number and address. *Keep in touch with the UNC GI Division!*

### INSIDE THIS ISSUE

- 2 Fellowship Update
- 3 Publications
- 4 UNC GI at DDW 2011
- 8 Appointments

### Annual Fund Donors FY10-11

Donald P. Brannan  
Joseph E. Cassara  
Leopold and Sara Cohen  
Bulent Ender  
Ralph and Shoshana Firman  
Barbara B. Forham  
John and Ruth Gay  
Jonathan and Susan Hansen  
Allen Hardy  
Susan J. Henning  
Joseph Johnson and Karen Diaz  
Alexander and Hiewon Kim  
Sidney and Alice Levinson  
Jill Macniven  
Ryan Madanick  
Roberta and Pamela McCall  
Claude T. Nuzum  
Rao Family Foundation  
Melissa Rich  
Robert S. Sandler  
Schwab Charitable Fund  
Phyllis C. Searle  
Victor and Judith Sears  
William and Ruth Smith  
Thomas and Donna Swankowski  
Syed I. Thiwan  
Goldie Towne  
Triangle Community Foundation  
Ryan C. Wanamaker  
Paul B. Watkins  
Stephan R. Weinland  
William Whitehead and Jan Busby-Whitehead  
Dia Winfree

## Best Doctors in America 2011-2012

More than 240 UNC physicians were listed in The Best Doctors in America 2011-2012 ratings, which was published in summary form in the November 2010 issue of Business North Carolina.

Overall, Only 3 to 5 percent of physicians in each country where Best Doctors is present are included in its database. The Best Doctors database contains the names and professional affiliations of approximately 45,000 doctors in the United States, all chosen through an exhaustive peer-review survey that asks: "If you or a loved one needed a doctor in your specialty, to whom would you refer them?" The peer review process as well as additional research conducted by Best Doctors determines selections for each list.

There were 11 members of the UNC GI Division included on this list: Eugene Bozyski, Evan Dellon, Douglas Drossman, Ian Grimm, Hans Herfarth, Kim Isaacs, Roy Orlando, Scott Plevy, Robert Sandler, Balfour Sartor, and Nicholas Shaheen.

## Faculty and Fellow Accomplishments

**Spencer Dorn** was appointed to the AGA Clinical Practice & Quality Management Committee.

**Douglas Drossman** coordinated the 9th International Symposium on Functional Gastrointestinal Disorders, which was held in Milwaukee, Wisconsin from April 8-10. This meeting is held every two years, and Dr. Drossman has been in this role since the meeting began in 1995.

**Michael Fried** was awarded a 5-year renewal of his NIH K24 Mid-Career Mentoring Award, which will provide Dr. Fried with continuing resources to mentor junior faculty and fellows in viral hepatitis research. He was also a coinvestigator on several presentations at the International Liver Congress (EASL) in Berlin Germany, including "Impact of IL28B genotype and pretreatment serum IP-10 in treatment naïve genotype-1 HCV patients treated with TMC435 in combination with Peginterferon alpha-2A and ribavirin" and "Telaprevir in combination with peginterferon alfa-2A and ribavirin increased sustained virologic response rates in treatment-naïve patients regardless of race or ethnicity".

**Jon Hansen** was awarded a K08 Career Development Award from NIH. He will be studying "Bacterial stress responses to intestinal inflammation".

**Hans Herfarth** was elected the chair of the Clinical Research Alliance (CRA) of the Crohn's and Colitis Foundation of America (CCFA). The CRA is a network of major medical centers and smaller, local facilities in the US, conducting clinical studies in inflammatory bowel diseases.

**Susan Henning** was the 2011 recipient of the Growth, Development and Aging Council Section Research Mentor Award, given by the AGA Institute. She will be presented with this award on Sunday May 8, during DDW.

**Udi Ringel** was one of eight gastroenterologists on an NIH working group with the National Human Genome Research Institute. Their goal was to create a consensus on high priority measures and recommend protocols to enable cross-study analysis of genome-wide association studies.

**Robert Sandler** was visiting professor this semester at University of Illinois Chicago and at Stanford. He was also featured in "28 of the Best Gastroenterologists in America" in Becker's ASC Review.

**Shehzad Sheikh** was awarded a Cornerstone Health Inc travel award to DDW.

## 4th Annual Patient Education Day for Inflammatory Bowel Disease

Over 150 physicians, pharmacists and nurses and more than 220 patients attended the CME event "3rd Update in IBD" and the "4th Annual Patient Education Day for Inflammatory Bowel Diseases", which both took place on September 11, 2010 at the Friday Center in Chapel Hill. Guest speakers Dr. David Binion, Co-Director of the Inflammatory Bowel Disease Center and Director of Translational IBD Research of University of Pittsburgh, and Dr. Douglas Drossman, Co-Director of the Center for Functional GI & Motility Disorders, University of North Carolina, and all IBD UNC faculty members Jonathan Hansen, Hans Herfarth, Kim Isaacs, Scott Plevy, Balfour Sartor and Millie Long taught at the events, which were a tremendous success.

## Publications

**Bulsiewicz W, Shaheen NJ.** The role of radiofrequency ablation in the management of Barrett's esophagus. *Gastrointest Endosc Clin N Am.* 2011; 21:95-109.

**Crockett SD, Long MD, Dellon ES, Martin CF, Galanko JA, Sandler RS.** Inverse relationship between moderate alcohol intake and rectal cancer: A case-control study. In press, *Dis Colon Rectum*, 2011

**Crockett SD, Martin C, Sandler RS, Kappelman M, Porter CQ.** Isotretinoin use and the risk of inflammatory bowel disease: A case-control study. *Am J Gastroenterology* 2010; 105: 1986-93.

**Darling JM, Aerssens J, Fanning G, McHutchison JG, Goldstein DB, Thompson AJ, Shianna KV, Afdhal NH, Hudson ML, Howell CD, Willem W, Bollekens J, De Wit M, Scholliers A, Fried MW.** Quantitation of pretreatment of serum IP-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. *Hepatology* 2011 (in press)

**Dellon ES, Chen X, Miller CR, Fritchie KF, Rubinas TC, Woosley JT, Shaheen NJ.** Tryptase staining of mast cells may differentiate eosinophilic esophagitis from gastroesophageal reflux disease. *Am J Gastroenterol*, 2011; 106: 264-71.

**Hansen JJ, Gulati A, Sartor RB.** The role of mucosal immunity and host genetics in defining intestinal commensal bacteria. *Curr Opin Gastroenterol* 2010; 26:564-71.

**Kanther M, Sun X, Mühlbauer M, Mackey LC, Flynn EJ 3rd, Bagnat M, Jobin C, Rawls J.** Microbial colonization induces dynamic temporal and spatial patterns of NF- $\kappa$ B activation in the zebrafish digestive tract. *Gastroenterology*. Epub Mar 23, 2011.

**Madanick RD.** PPI side effects and drug interactions: much ado about nothing? *Cleve Clin J Med* 2011;78:39-49.

**Madanick RD, Shaheen NJ, Dellon ES.** A novel balloon pull-through technique for esophageal dilation in eosinophilic esophagitis (and video). *Gastrointest Endosc* 2011;73:138-42.

**Madanick RD, Long MD, Shaheen NJ.** Letter to the Editors: Ascertainment bias increases estimate of risk of GERD in depressed patients. *Aliment Pharmacol Ther* 2010;32:508-9.

**Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J, Kleiner DE, Hayashi PH; DILIN Research Group.** Clinical and Histopathologic Features of Fluoroquinolone-induced Liver Injury. *Clin Gastroenterol Hepatol*. Epub Feb 26, 2011.

**Peery AF, Cao H, Dominik R, Shaheen NJ, Dellon ES.** Variable reliability of endoscopic findings with white light and narrow band imaging for patients with eosinophilic esophagitis. *Clin Gastroenterol Hepatol*, 2011. Epub March 3, 2011

**Peery AF, Shaheen NJ, Dellon ES.** Practice patterns for the evaluation and treatment of eosinophilic esophagitis: A survey of academic and community gastroenterologists. *Aliment Pharmacol Ther*, 2010; 32: 1373-82.

**Sheikh S, Hegazi RH, Kobayashi T, Matsuoka K, Sepulevda S, Otterbein LE, Plevy SE.** An Anti-Inflammatory Role for Carbon Monoxide and Heme Oxygenase-1 in Chronic T-helper-2 mediated Murine Colitis" *J Immunol*, in press 2011.

**Sheikh S, Kobayashi T, Matsuoka K, Onyiah J, Plevy, SE.** Characterization of an interferon-stimulated response element (ISRE) in the IL23a promoter. *J Biol Chem*. 2011 Jan 14;286(2):1174-80.

**Sheikh S, Plevy SE.** The role of the macrophage in sentinel responses in intestinal immunity. *Curr Opin Gastroenterol*. 2010 Nov;26(6):578-82.

**Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ.** Ribavirin potentiates interferon action by augmenting interferon stimulated gene induction in hepatitis C virus cell culture models. *Hepatology* 2011 (in press)

## Patient Education Day for Inflammatory Bowel Disease (continued)

Course director Hans Herfarth reports a steady increase of participants in both courses over the last 3 years. Both events, which covered topics such as "risk of intestinal infections, irritable bowel syndrome and IBD, the future of biological therapies and individualized therapy in IBD" received excellent ratings from the participants. The next 5th IBD Patient Education Day" and the 4th CME- IBD Update with the guest speakers Dr. McGovern, Director of Translational Medicine at the Inflammatory Bowel Diseases Center and Immunobiology Institute of the Cedars-Sinai Medical Center in Los Angeles and Dr. Rahbar and Dr. Kappelman, Department of Surgery and Pediatric Gastroenterology, respectively, at the University of North Carolina is planned for Saturday, September 10, 2011. The topics will include "The true value of genetic and serologic testing in IBD", "Quality control of IBD care," "Surgical and medical care of fistulizing Crohn's disease" and several talks on new aspects of biologic and non-biologic therapy in IBD. Additionally interactive IBD case discussions are planned.

Division Faculty will again be well-represented at DDW 2011, held in Chicago, Illinois. Selected oral, poster, and invited presentations are listed below.

### Oral Presentations

**CD24 as a Potential Marker to Directly Isolate Lgr5+ Colonic Epithelial Cells.** King JB, von Furstenberg RJ, Henning SJ.

**Impact of the 2008-2009 Economic Recession on Colonoscopy Utilization Among the Insured.** Dorn SD, Wei D, Farley JF, Shah ND, Shaheen NJ, Sandler RS, Kappelman MD.

**Dietary Fiber is Not Associated with Diverticulosis.** Peery AF, Barrett PR, Park D, Rogers AJ, Locklear T, Galanko JA, Martin CF, Sandler RS.

**Is the Effect of Lubiprostone on Clinical Pain Mediated by Decreases in Visceral Pain Sensitivity?** Whitehead, W.E.

**Therapeutic Impact of Mindfulness Meditation on Irritable Bowel Syndrome (IBS): Results of a Randomized Controlled Trial.** Whitehead, W.E.

**Targeting the mTOR signaling prevents and treats Campylobacter jejuni-induced colitis.** Sun X, Jobin C.

**Chair: Colitis-associated cancer: basic and translational mechanisms.** Jobin, C

**Excess co-morbidity in IBS: Increased neural sensitivity or response bias?** van Tilburg MAL, Palsson OS, Kanazawa M, Turner M, Whitehead WE.

**Mitochondrial Inheritance in One-Sixth of Adults With Irritable Bowel Syndrome.** van Tilburg MAL, Zaki EA, Boles RG.

**“Probiotics and Prebiotics” in the focused research roundtable discussion Probiotics and Prebiotics (invited presentation).** Ringel Y.

**Irgm1 deficiency selectively affects intestinal Paneth cell morphology and function.** Liu B, Gulati AS, Luo G, Holt LC, Taylor G, Sartor RB.

**Genetics Play a Role in Diverticular Disease: Results from the Danish Twin Registry.** Strate LL, Erichsen R, Baron JA, Mortensen J, Pedersen JK, Christensen K, Sorensen HT.

**How Much Pharyngeal Acid is “Normal?”: Normative Data for Laryngopharyngeal Reflux Events Using Hypopharyngeal Multichannel Intraluminal Impedance (HMI).** Hoppo T, Sanz AF, Nason KS, Carroll T, Rosen C, Normolle DP, Shaheen NJ, Luketich JD, Jobe BA.

**Excess co-morbidity in IBS: Increased neural sensitivity or response bias?** Whitehead, W. E.

**ASGE Hands-on Workshop: Endoscopic Tools for the Bariatric Patient.** Morgan DR

**“Intestinal Microbiota in GI Disorders and Diseases” in the translational symposium Barrier Function and Intestinal Homeostasis (invited presentation).** Ringel Y.

**Feasibility, Safety and Acceptability of Office-based, Screening Transnasal Endoscopy.** Peery AF, Garman KS, Daugherty N, Hoppo T, Bream S, Sanz AF, Spacek M, Connors D, Faulx AL, Chak A, Luketich JD, Shaheen NJ, Jobe BA.

**Meet-the-Investigator: Animal Models Of Inflammatory Bowel Disease.** Jobin, C.

**A randomized trial comparing 14-day triple, 10-day sequential, and 5-day concomitant therapy to eradicate Helicobacter pylori in seven Latin American populations.** Ferreccio C, Anderson GL, Morgan DR, Torres J, Bravo LE, Dominguez R, Herrero R, Meza MM, Peña R, Salazar E, Chey WD, Valdivieso M, Crowley J, Greenberg ER, Baker LH.

**Markers of tyrosine kinase activity for diagnosis and treatment response in eosinophilic esophagitis: A pilot study of pERK 1/2 and pSTAT5.** Dellon ES, Bower JJ, Sui W, Keku TO, Chen X, Miller CR, Livasy CA, Woosley JT, Orlando RC, Shaheen NJ.

**Advanced Colorectal Neoplasia Yield at the One-year Colonoscopy Following Polypectomy: Results of a Pooled Analysis.** Atkin W, Ashbeck EL, Baron JA, Robertson DJ, Lieberman DA, Ahnen DJ, Jacobs ET, Schatzkin A, Greenberg ER, Martínez ME.

**Barrett’s Dysplasia Cancer Task force - BAD CAT: A global, multidisciplinary, consensus on the management of high grade dysplasia and early mucosal cancer in Barrett’s esophagus.** Jankowski JA, Vaki NB, Ferguson MK, Bennett C, Moayyedi P, Bergman JJ, Harrison RF, Barr H, deCaestecker J, Inadomi JM, Shaheen NJ, Meltzer SJ, Fennerty MB, Waxman I, Ragunath K, Kahrilas PJ, Attwood SE, Vieth M, Gay LJ, Krishnadath KK, Longcroft-Wheaton GR, Singh R, Armstrong D, Wang KK, Bhandari P, Poller D, Yerian L, Hongo M, Kay E, Sanders S.

**Durability of Reversion to Neosquamous Epithelium follow Radiofrequency Ablation for Dysplastic BE: Longterm Follow-up of the AIM Dysplasia Trial.** Shaheen NJ, Wang KK, Wolfsen HC, Fleischer DE, Overholt BF, Galanko JA, Lightdale CJ.

**Inflammation impacts the development of colorectal**

**cancer through changes in microbial composition and associated genotoxic capacity.** Arthur JC, Uronis JM, Chanona EP, Keku TO, Muehlbauer M, Tomkovich SE, Fan TJ, Hansen JJ, Jobin C.

**“Endoscopic diagnosis of eosinophilic esophagitis” in the clinical symposium Endoscopic diagnosis and management of eosinophilic esophagitis (invited presentation).** Dellon ES.

**Association of Low Dietary Intake of Fiber and Liquids with Constipation: Evidence from the National Health and Examination Survey (NHANES).** Whitehead, W.E.

### Poster Presentations

**\*\*On-therapy Versus Off-therapy Testing in Patients with Symptoms of Refractory Gastroesophageal Reflux Disease: a Cost-Utility Analysis.** Madanick RD, Kass S, Shaheen NJ.

**\*\*The effect of operator experience on treatment of dysplastic Barrett’s esophagus with radiofrequency ablation.** Bulsiewicz WJ, Pasricha S, Dellon ES, Pettulo BT, Madanick RD, Shaheen NJ.

**\*Mucosal Adherent Bacteria, Inflammation and Colorectal Adenomas.** Araujo-Perez, F; Sanapareddy, N; McCoy, AN.; Jovov, B; Benson, AK.; Abdo, Z; Fodor, A; Sandler, R S.; Keku, TO.

**Development and Validation of the Irritable Bowel Syndrome Satisfaction with Care Scale (IBS-SAT).** Dorn SD, Morris CB, Schneck SE, Hopper TM, Hu JB, Kulkarni R, Weinland SR, Norton WF, Norton NJ, Drossman DA.

**The Escherichia coli stress response genes gadAB are differentially regulated during experimental colitis.** Fan TJ, Sartor RB, Hansen JJ.

**Molecular Characterization of the Fecal and Colonic Mucosal-Associated Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Patients.** Carroll IM, Kulka-Ringel T, Keku TO, Chang YH, Packey CD, Neil SK, Williamson D, Sartor RB, Ringel Y.

**The efficacy and predictors of stricture formation following radiofrequency ablation for Barrett’s esophagus at a tertiary referral center.** Bulsiewicz WJ, Pasricha S, Dellon ES, Madanick RD, Spacek MB, Orlando RC, Shaheen NJ.

**Predictors of difficulty eradicating Barrett’s esophagus with radiofrequency ablation.** Bulsiewicz WJ, Pasricha S, Dellon ES, Madanick RD, Shaheen NJ.

**Sub-Optimal Barrier Function in Neosquamous Epithelium following Ablative Therapy.** Jovov B, Tobey N, Shaheen NJ, Djukic Z, Orlando GS, Orlando RC.

**An In Vitro and In Vivo Analysis of MicroRNA in the Pathogenesis of Barrett’s Esophagus.** Garman KS, Anderson B, Zhang X, Huo X, Diehl AM, Souza RF, Shaheen NJ.

**Constitutively active tyrosine kinase due to the FIP1L1-PDGFRα fusion protein: A potential non-allergic pathogenic mechanism in eosinophilic esophagitis?** Dellon ES, Bower JJ, Keku TO, Chen X, Miller CR, Livasy CA, Woosley JT, Orlando RC, Shaheen NJ.

**Effect of guidelines for eosinophilic esophagitis on variability of diagnostic criteria in the medical literature.** Sperry SLW, Shaheen NJ, Dellon ES.

**Time trends in foreign body impactions in the esophagus: What is the impact of the increasing prevalence of eosinophilic esophagitis?** SperrySLW, Crockett SD, Miller CB, Shaheen NJ, Dellon ES.

**Reliability of endoscopic findings in eosinophilic esophagitis with white light and narrow band imaging.** Peery AF, Cao H, Dominik R, Shaheen NJ, Dellon ES.

**The clinical utility of endoscopic ultrasound before ablation in patients with Barrett’s esophagus and high-grade dysplasia or intramucosal carcinoma.** Bulsiewicz WJ, Rogers AJ, Dellon ES, Pasricha S, Madanick RD, Grimm IS, Shaheen NJ.

**A Cross-sectional Analysis of the Prevalence of Barrett’s Esophagus in Otolaryngology Patients with Laryngeal Symptoms.** Murphy TJ, Nason KS, Shaheen NJ, Schindler JS, Schipper PH, Hoppo T, Diggs BS, Sauer DA, Morris C, Luketich JD, Jobe BA.

**Yield of Transnasal Endoscopy in an Unselected General Medical Population.** Garman KS, Peery AF, Daugherty N, Hoppo R, Bream S, Sanz AF, Spacek M, Connors D, Faulx AL, Chak A, Luketich JD, Jobe BA, Shaheen NJ.

**Inflammatory Bowel Disease Activity and Narcotic Use During Hospitalization.** Long MD, Barnes EL, Herfarth HH, Drossman DA.

**Narcotic Bowel Syndrome: Characterization of 30 patients and preliminary results after detoxification.** Drossman DA, Morris CB, Davis CE, Weinland SR, Aderoju AO, Kulkarni-Kelapure RR, Hu YJ, Houpe ME, Zimmerman J, Rooker C, Bangdiwala SI.

**Prevalence of esophageal mucosal breaks in patients with gastroesophageal reflux disease who have a partial response to proton pump inhibitor therapy.** 1037548 Shaheen NJ, Denison H, Björck K, Silberg DG.

**Development and validation of a Natural Language Processing computer program to evaluate the quality of colonoscopy reports.** Harkema H, Bishehsari F, Dellon ES, Saul M, Chapman W, Farmer C, Mehrotra A, Schoen RE.

**Increased Stomach Aches in Children are Associated with Parent IBS Status and Maladaptive Parenting in Japan.** Whitehead, W.E.

**Increased Postprandial Colonic Motility is Associated with Sympathetic Nerve Activity in Patients with Irritable Bowel Syndrome.** Whitehead, W.E.

**Predictive Factors in the Development of Post-Infectious Irritable Bowel Syndrome.** Whitehead, W.E.

**Diffuse Noxious Inhibitory Controls (DNIC) are Compromised in Patients with Irritable Bowel Syndrome (IBS) Compared to Healthy Controls (HC).** Whitehead, W.E.

**Temporal Summation in Patients with Irritable Bowel Syndrome (IBS) Compared to Healthy Controls (HC).** Whitehead, W.E.

**The neuropeptide DALDA protects against NSAID-induced acute intestinal injury in zebrafish larvae.** Goldsmith JR, Rawls JF, Jobin C.

**U.S. Patients with Chronic Abdominal Pain are Increasingly Prescribed Opioid Analgesics.** Dorn SD, Meek PD, Shah ND.

**Intestinal Fermentation Assessed by Intraluminal pH in Subjects with Abdominal Bloating.** Ringel-Kulka T, Siddle JP, Maier DM, Galanko JA, Semler JR, Ringel Y.

**Efficacy of a novel  $\gamma$ -aminobutyric acid type B receptor (GABAB) agonist, lesogaberan, as an add-on to proton pump inhibitor (PPI) therapy in the treatment of gastroesophageal reflux disease in patients who have a partial response to PPI therapy.** Shaheen NJ, Denison H, Björck K, Karlsson, M Silberg DG.

**Safety profile of a novel  $\gamma$ -aminobutyric acid type B receptor (GABAB) agonist, lesogaberan, as an add-on to proton pump inhibitor (PPI) therapy in the treatment of gastroesophageal reflux disease in patients who have a partial response to PPI therapy.** Shaheen NJ, Denison H, Björck K, Silberg DG.

**Mu opioid signaling and STAT3 activation protects against acute murine intestinal injury in mice.** Goldsmith JR, Uronis J, Gipson G, Jobin C.

**Liver-Specific mRNAs are Present in Cell-free Plasma in Man and May Serve as Novel Biomarkers for Drug-Induced Liver injury (DILI).** Nowrouzzadeh F, Wetmore B, Hayashi PH, Thomas RS, Watkins PB.

**The Probiotic Bacteria Lactobacillus acidophilus NCFM® (L-NCFM) and Bifidobacterium lactis Bi-07 (B-LBi07) Increase Expression of Intestinal Opioid Receptors - First Evidence in Humans.** Ringel Y, Goldsmith JR, Carroll IM, Siddle JP, Jobin CJ, Barros SP, Ringel-Kulka Y.

**Esophageal foreign body impaction presenting to the emergency department: Time trends, utilization, and treatment modalities.** Sperry SLW, Crockett SD, Miller CB, Shaheen NJ, Dellon ES.

**How good are individuals at predicting diarrhea based on perceived triggers and warning sensations?: A diary study.** Whitehead, W.E.

**Influence of Stool Consistency, Urgency, and Obstetric History on Fecal Incontinence.** Whitehead, W.E.

**Utility of Physical Examination and Questionnaire for Identifying Patients who do not have Dyssynergic Defecation.** Whitehead, W.E.

**Utility of the Balloon-Evacuation Test for Identifying Patients with Dyssynergic Defecation.** Whitehead, W.E.

**Detection and Quantification of Intestinal Inflammation in vivo and ex vivo by Activatable Molecular Probes.** Ding S, Blue E, Bradford J, Morgan DR, Lund PK.

### Session Moderators

**Bariatric Procedures, ASGE.** Gangarosa, L

**Accountable Care Organizations and What it Means for the Practice of Gastroenterology for the Gastroenterologist.** Dorn, SD

**Eosinophilic esophagitis: New understanding in pathogenesis.** Dellon, ES.

**Evaluating Sequential Therapies for Eradication of H. pylori Infection.** Morgan DR.

Outpatient general endoscopic procedures such as colonoscopy, EGD, and sigmoidoscopy can be scheduled directly through the GI Procedure Unit (919-966-5563; after hours, messages may be left at 919-966-2319).

These are considered "open access" procedures, meaning that they can be scheduled by any referring physician. Services provided by the UNC Motility Unit are also "open access". All other procedures require approval by a UNC faculty member (after completion of a referral form or following a telephone consultation).

For questions regarding urgent or complex cases, call the GI Procedures Unit (919-966-5563) and ask to speak to an attending physician in the procedures area.

## Clinic Appointments

Phone: GI Program - (919) 966-2511 - Hepatology Program - (919) 966-2516

Fax: GI Program - (919) 966-3414 - Hepatology Program - (919) 966-1700

Division of Gastroenterology & Hepatology  
UNC School of Medicine  
130 Mason Farm Road  
CB # 7080 Biostatistics Building  
Chapel Hill, NC 27599-7080